The power and limitations of immunobridging studies: the example of COVID-19 vaccines


Discussion topic:
The power and limitations of immunobridging studies: the example of COVID-19 vaccines
 
Chair: Hanna Nohynek,
Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee
Presentations :

Bridging studies – why and how?
Peter Dull, Bill & Melinda Gates Foundation

Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA. Marco Cavaleri, Head of Office Biological Health Threats and Vaccine Strategy, European Medicines Agency.

Panel discussion:  Strategies behind the variant adapted COVID-19 vaccines development
with participation from regulators, Godwin Enwere, WHO Prequalification Unit, Vikram Paradkar, Executive Vice-President   Production, Biological E, representing DCVMN, Jeff Roberts, Associate Vice-President Clinical Research, MSD, representing   IFPMA, and other experts.


HPV vaccination: Prospect of moving to a one and only dose schedule


Discussion topic:
HPV vaccination: Prospect of moving to a one and only dose schedule
 
HPV Vaccination: The evidence in favour of a one and only dose schedule and its limitations
Presenter: Margaret Stanley, University of Cambridge, UK
Chair : Philippe Duclos, Director of ADVAC, University of Geneva

Safety of COVID-19 Vaccines


Discussion topic:
Safety of COVID-19 Vaccines
There will be two main presentations as follows:

COVID-19 Vaccine Safety – Perspective from WHO’s Global Advisory Committee on Vaccine Safety
Presenter: Rita Helfand, Chair, Global Advisory Committee on Vaccine Safety, WHO, and Senior Advisor for Science, National Center for Emerging and Zoonotic Infectious Diseases, CDC

COVID-19 Vaccine Safety – US experience
Presenter: Tom Shimabukuro, Acting Director, Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Chair: Melinda Wharton, Associate Director for Vaccine Policy, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention (CDC) and Member of the ADVAC Scientific Committee

COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity? (S4)



Discussion topic:
Vacunas contra el COVID: ¿Hay necesidad de refuerzos en vista de la aparición de nuevas variantes y la disminución de la inmunidad?
Session 4 (en español)

Presidente: Professor Romina Libster, Fundación INFANT, Argentina y profesora del ADVAC


Disertantes:
Professor Cristiana Toscano, Federal University of Goiás, Brazil
Evidencia para orientar la decisión sobre los esquemas de refuerzos de la vacunación contra COVID-19 ¿Qué sabemos y qué no sabemos?

Professor Celia Alpuche, Instituto Nacional de Salud Publica, Mexico
Desafíos y complejidades en el proceso de toma de decisiones para la vacunación COVID-19: experiencia de América Latina

Discusion:
Professor Alejandro Cravioto, Universidad Nacional Autónoma de México y Presidente del SAGE


COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity? (S3)


Discussion topic:
COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity?
Session 3 : 17:00-19:00 - (english)

Chair: Professor Anna Durbin, Johns Hopkins Bloomberg School of Public Health, USA and Member of the ADVAC Scientific Committee


Presenters:
Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
Booster versus 2+1 primary immunisation vaccination: Does it matter?

Professor Stanley Plotkin, University of Pennsylvania, USA
Correlates of Protection as Indicators for Third Doses of COVID Vaccines

COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity? (S2)


Discussion topic:
Vaccins COVID - est-il nécessaire de procéder à des rappels compte tenu de l'émergence de variants et de la baisse de l'immunité dans le temps?
Session 2 : 14:00-16:00 - (en français)

Président: Prof. Paul-Henri Lambert, Université de Genève et Membre du comité scientifique d’ADVAC


Orateurs:
Dre Christiane Eberhardt et Prof. Arnaud Didierlaurent, Université de Genève
Pour quoi, pour qui et pour quand? La 3ème dose du vaccin COVID-19 en question !

COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity? (S1)


Discussion topic:
COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity?
Session 1 : 10:00-12:00 - (english)

Chair: Dr Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland and Member of the ADVAC Scientific Committee


Presenters:
Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
Booster versus 2+1 primary immunisation vaccination: Does it matter?

Dr Jerome Kim, International Vaccine Institute, Seoul, Republic of Korea
The booster in your future: when, what, and why?


Will the success of mRNA vaccine development platforms for COVID-19 lead to new platforms for old vaccines?


Discussion topic:
Will the success of mRNA vaccine development platforms for COVID-19 lead to new platforms for old vaccines?
There will be two main presentations as follows:

The Immunological benefits of mRNA and potential applications
Presenter:  Barney Graham, previously with the National Institute of Health, USA

Regulatory approaches:  Issues and challenges, and questions to be asked by regulators
Presenter:  Philip Krause, Food & Drug Administration, USA

Dr Martin Friede, WHO will chair the meeting.


Logistics of deployment of COVID vaccines on a global level


Discussion topic:
Logistics of deployment of COVID vaccines on a global level  - how vaccines will make it to the most vulnerable populations 
Presenters:
Professor Lisa Cooper, Johns Hopkins Bloomberg School of Public Health
Dr Katherine O’Brien, WHO
Chairs:
Professor Anna Durbin, John Hopkins Bloomberg School of Public Health
Dr Emily Erbelding, NIAID/National Institutes of Health, USA.

Contextualization of the results of COVID vaccine trials


Discussion topic:
Contextualization of the results of COVID vaccine trials: implications for national decision-making, future and ongoing trials, and post-licensure surveillance
Presenter:  Professor Peter Smith, London School of Hygiene and Tropical Medicine, UK
Title of presentation:  Early results from COVID-19 vaccine trials and implications for ongoing and future trials of other COVID-19 vaccines
Presenter:  Professor Nick Andrews, Public Health England, UK
Title of presentation:  Approaches to study vaccine impact post-licensure, both vaccine effectiveness and safety
Webinar : Wednesday, 9 December 2020
Documents and links:
pdfEarly results from COVID-19 vaccine trials and implications for ongoing and future trials of other COVID-19 vaccines (pdf file)
Presentation of Peter Smith
pdfApproaches to study vaccine impact post-licensure, both vaccine effectiveness and safety (pdf file)
Presentation of Nick Andrews

Polio Eradication Endgame: A Novel Oral Polio Vaccine On The Horizon

Discussion topic:
Polio Eradication Endgame: a novel oral polio vaccine on the horizon
Presenter:  Dr Ananda Bandyopadhyay, Bill & Melinda Gates Foundation
Webinar : Tuesday, 26 May 2020.
Documents and links:
pdfPresentation of Ananda S. Bandyopadhyay:
Polio Eradication Endgame: A Novel Oral Polio Vaccine On The Horizon.
 
(pdf file)
pptPresentation of Ananda S. Bandyopadhyay:
Polio Eradication Endgame: A Novel Oral Polio Vaccine On The Horizon.
(pptx file)

Vaccine development platforms: application to coronavirus (progress and challenges)

Discussion topic:
Discussion topic:  Vaccine development platforms: application to coronavirus (progress and challenges)
Presenters: Dr Barney Graham, NIH, USA and Dr Melanie Saville, CEPI
Webinar : Thursday, 2 April 2020.
Documents and links:
pdfPresentation of Barney Graham: Prototype pathogen approach to pandemic preparedness. (pdf file)
pdfPresentation of Melanie Saville: Covid-19 vaccine development platforms. (pdf file)